urocap iii - uroflowmetry system
עינת מדיקל סוכנויות בע"מ - אחות - תבחין זרימת שתן
disposable devices for general floor use
kencap ltd. - כלל האוכלוסיה - ציוד חד פעמי לשימוש חיצוני בבתי חולים ומרפאות )מספרים, פינצטות, קלמים,מראות דנטליות וכו'(
ביקאלוטמיד אינובמד 150 מג
inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable
מונטהלוקאסט אינובמד 5 מ"ג
inovamed ltd - montelukast as sodium 5 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 6 to 14 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 to 14 years of age.
מונטהלוקאסט אינובמד 4 מ"ג
inovamed ltd - montelukast as sodium 4 mg - chewable tablets - montelukast - montelukast inovamed is indicated in pediatric patients 2 to 5 years of age for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 to 5 years of age.
מונטהלוקאסט אינובמד 10 מ"ג
inovamed ltd - montelukast as sodium 10 mg - film coated tablets - montelukast - montelukast inovamed is indicated in adult and adolescents 15 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction.montelukast inovamed is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. montelukast inovamed and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. montelukast inovamed is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and adolescents 15 years of age and older.
רמיפריל אינובמד 10
inovamed ltd - ramipril - טבליה - ramipril 10 mg - ramipril
רמיפריל אינובמד 2.5
inovamed ltd - ramipril - טבליה - ramipril 2.5 mg - ramipril
רמיפריל אינובמד 5
inovamed ltd - ramipril - טבליה - ramipril 5 mg - ramipril
אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל
inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.